PLYGF (PolyPeptide Group AG) 3-Year Share Buyback Ratio: -0.10% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLYGF PolyPeptide Group AG PLYGF
60 GF Score
Price $54.42
GF Value $41.28
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is PolyPeptide Group AG 3-Year Share Buyback Ratio?

PolyPeptide Group AG PLYGF +26.56% 60 3-Year Share Buyback Ratio is -0.10 as of Dec. 2025. GuruFocus rates PLYGF with a GF Score™ of 60/100 and a GF Value™ of $41.28 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 647 Drug Manufacturers companies, PolyPeptide Group AG ranks better than 74.65% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. PolyPeptide Group AG's current 3-Year Share Buyback Ratio was -0.10%.

The historical rank and industry rank for PolyPeptide Group AG's 3-Year Share Buyback Ratio or its related term are showing as below:

PLYGF' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -0.1   Med: 0.1   Max: 0.1
Current: -0.1

During the past 8 years, PolyPeptide Group AG's highest 3-Year Share Buyback Ratio was 0.10%. The lowest was -0.10%. And the median was 0.10%.

PLYGF's 3-Year Share Buyback Ratio is ranked better than
74.65% of 647 companies
in the Drug Manufacturers industry
Industry Median: -1.9 vs PLYGF: -0.10

PolyPeptide Group AG (OTCPK:PLYGF) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


PolyPeptide Group AG 3-Year Share Buyback Ratio Related Terms


PLYGF vs ZTS, UTHR, VTRS: 3-Year Share Buyback Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PolyPeptide Group AG 3-Year Share Buyback Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's 3-Year Share Buyback Ratio falls into.


PLYGF
60GF Score
PolyPeptide Group AG PLYGF
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -0.10 mean?
PolyPeptide Group AG (PLYGF) has a 3-Year Share Buyback Ratio of -0.10 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for PolyPeptide Group AG and its competitors. According to the industry distribution chart, PolyPeptide Group AG ranks #164 out of 647 companies in the Drug Manufacturers industry, placing it in the top 25.3%.
Is PolyPeptide Group AG's 3-Year Share Buyback Ratio too high?
PolyPeptide Group AG's current 3-Year Share Buyback Ratio is -0.10. Based on the distribution chart, PolyPeptide Group AG ranks #164 out of 647 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PolyPeptide Group AG has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's 3-Year Share Buyback Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PolyPeptide Group AG ranks #164 out of 647 companies for 3-Year Share Buyback Ratio. This puts PolyPeptide Group AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current 3-Year Share Buyback Ratio is -0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $41.28, compared to a current price of $54.42 — trading 31.8% above its estimated fair value. The current 3-Year Share Buyback Ratio is -0.10. PolyPeptide Group AG's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current 3-Year Share Buyback Ratio is -0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of $54.42 is trading 31.8% above its estimated GF Value™ of $41.28. GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.

Key valuation signals for PLYGF:

  • 3-Year Share Buyback Ratio: -0.10
  • GF Value™: $41.28 vs. price of $54.42 (31.8% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
60GF Score

Get the complete analysis for PLYGF

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.42
Price
$41.28
GF Value